The overexpression of SOS1 in CML led us to hypothesize that targeting SOS1 may show anti-CML activity and confer a therapeutic benefit in CML patients. This evidence concerns the gene SOS1 and chronic myelogenous leukemia, BCR-ABL1 positive.